1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Pakistan Pharmaceuticals and Healthcare Report Q1 2016

Pakistan Pharmaceuticals and Healthcare Report Q1 2016

  • November 2015
  • -
  • Business Monitor International
  • -
  • 106 pages

Includes 3 FREE quarterly updates

BMI View: Healthcare access will remain limited by Pakistan's fragmented medical system. Effectiveimprovements to this will require a consolidation of healthcare policy, as the devolution of responsibilitiesto provincial authorities have created uneven healthcare access while Pakistan's mixed medical deliverymodel sees overlapping services and wastage. However, such a move is unlikely given the lack of policycontinuity in the country, thus demanding that pharmaceutical firms scope their strategies at the provinciallevel while accounting for the highly fragmented delivery of healthcare.

Headline Expenditure Projections

- Pharmaceuticals: PKR231.23bn (USD2.29bn) in 2014 to PRK252.42bn (USD2.46bn) 2015; +9.2%inlocal currency terms and +7.3% in US dollar terms.

- Healthcare: PKR698.82bn (USD6.92bn) in 2014 to PKR773.22bn (USD7.52n) in 2015; +10.6% in localcurrency terms and +8.8% in US dollar terms.

Table Of Contents

Pakistan Pharmaceuticals and Healthcare Report Q1 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Pakistan 2013-2019) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Pakistan 2011-2019) 13
Healthcare Market Forecast 14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Pakistan 2011-2019) 16
Table: Government Healt Expenditure Trends, Historical Data And Forecasts (Pakistan 2010-2018) 17
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Pakistan 2011-2019) 17
Prescription Drug Market Market 18
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Pakistan 2011-2019) 20
Patented Drug Market Forecast 21
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Pakistan 2011-2019) 22
Generic Drug Market Forecast 23
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Pakistan 2011-2019) 25
OTC Medicine Market Forecast 26
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Pakistan 2011-2019) 27
Pharmaceutical Trade Forecast 28
Table: Pharmaceutical Trade Data And Forecasts (Pakistan 2013-2019) 30
Table: Pharmaceutical Trade Data And Forecasts local currency (Pakistan 2013-2019) 30
Industry Risk Reward Index 31
Asia Pacific Risk/Reward Index 31
Pakistan Risk/Reward Index 38
Rewards 38
Risks 38
Regulatory Review 39
Regulatory Developments 42
Intellectual Property Issues 42
Pricing Regime 43
Reimbursement Regime 45
Market Overview 47
Healthcare Sector 48
Table: Healthcare Resources (Pakistan 2009-2014) 50
Table: Healthcare Personnel (Pakistan 2009-2014) 50
Table: Healthcare Activity (Pakistan 2009-2014) 51
Research and Development 51
Clinical Trials 52
Epidemiology 53
Table: Diabetic Patients' Education Level and Compliance Levels 55
Table: Estimated Number Of New Cases Of Cancer In Pakistan 56
Table: Frequency Of Information Provided To Patients As A Percentage Of Total Cases 57
Competitive Landscape 59
Research-Based Industry 59
Table: Multinational Market Activity 59
Generic Drugmakers 60
Table: PPMA As Of 2015 61
Pharmaceutical Distribution 64
Company Profile 66
Abbott Laboratories 66
Efroze Chemical Industries 69
Ferozsons Laboratories 72
Getz Pharma 75
GlaxoSmithKline (GSK) 78
Hilton Pharma 82
Novartis 84
Pfizer 87
Sanofi-Aventis 90
Searle Pakistan Limited 93
Demographic Forecast 95
Table: Population Headline Indicators (Pakistan 1990-2025) 96
Table: Key Population Ratios (Pakistan 1990-2025) 96
Table: Urban/Rural Population and Life Expectancy (Pakistan 1990-2025) 97
Table: Population By Age Group (Pakistan 1990-2025) 97
Table: Population By Age Group % (Pakistan 1990-2025) 98
Glossary 100
Methodology 102
Pharmaceutical Expenditure Forecast Model 102
Healthcare Expenditure Forecast Model 102
Notes On Methodology 103
Risk/Reward Index Methodology 104
Index Overview 105
Table: Pharmaceutical Risk/Reward Index Indicators 105
Indicator Weightings 106

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7 000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

IMS World Review Executive™ 2016

IMS World Review Executive™ 2016

  • $ 6 860
  • Industry report
  • July 2016
  • by IMS Health

IMS World Review ExecutiveTM 2016 provides essential insights into worldwide sales of the pharmaceutical market, interlocking market trends and sales analysis from 2011 to 2015, including the breakdown ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.